FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy optionThe FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected Share XFDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy optionhttps://pharmaphorum.com/news/fda-review-of-lilly-innovents-sintilimab-paves-way-for-cut-price-immunotherapy-option/
